Cargando…

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial

OBJECTIVE: Animal studies demonstrated that glucagon-like peptide-1 receptor agonists reduce myocardial necrosis following regional ischaemia induction. This effect may improve cardiovascular outcomes after myocardial infarction. Risk of cardiovascular death or hospitalisation for heart failure afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael A, Tornøe, Karen, Rasmussen, Søren, Treppendahl, Marianne Bach, Marso, Steven P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130125/ https://www.ncbi.nlm.nih.gov/pubmed/29947247 http://dx.doi.org/10.1177/1479164118783935

Ejemplares similares

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
por: Nauck, Michael A., et al.
Publicado: (2020)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials
por: Davies, M. J., et al.
Publicado: (2017)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Liraglutide for weight management: a critical review of the evidence
por: Mehta, A., et al.
Publicado: (2016)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction
por: Qi, Quan, et al.
Publicado: (2017)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
por: Hoshika, Yu, et al.
Publicado: (2021)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014)

Leader–member exchanges with leaders who have worked for 25 years in health institutions
por: Vasset, Frøydis, et al.
Publicado: (2023)

Mode of arrival does not predict myocardial infarction in patients who present to the ED with chest pain
por: Weiner, Scott G., et al.
Publicado: (2009)

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
por: Funch, D, et al.
Publicado: (2014)

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
por: Kalra, Sanjay
Publicado: (2016)

Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: Secondary analyses of a randomised controlled trial
por: Bartholdy, Cecilie, et al.
Publicado: (2022)

Just a leader? Leadership work challenges and identity contradiction experienced by Finnish physician leaders
por: Huikko-Tarvainen, Sari, et al.
Publicado: (2021)

LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ
por: Rutten, Guy E. H. M., et al.
Publicado: (2016)

Counting Is Easier while Experiencing a Congruent Motion
por: Lugli, Luisa, et al.
Publicado: (2013)

TRANSITIONS EXPERIENCED BY PEOPLE DIAGNOSED WITH DEMENTIA WHILE IN THE WORKFORCE
por: Boger, Jennifer, et al.
Publicado: (2022)

Who Has Seen Patients With ST‐Segment–Elevation Myocardial Infarction? First Results From Italian Real‐World Coronavirus Disease 2019
por: Cammalleri, Valeria, et al.
Publicado: (2020)

Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction
por: Cottin, Yves, et al.
Publicado: (2021)

Clinicians as Leaders: Impact and Challenges
por: Khan, Rehan Nasir, et al.
Publicado: (2022)

Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
por: Bruinstroop, Eveline, et al.
Publicado: (2018)

Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting
por: Unger, Jeff, et al.
Publicado: (2019)

Barriers to Care Experienced by Patients Who Inject Drugs During the COVID-19 Pandemic: A Qualitative Analysis
por: Gleason, Emily, et al.
Publicado: (2022)

Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction
por: Chung, Jae-Wook, et al.
Publicado: (2021)

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
por: Noyan-Ashraf, Mohammad Hossein, et al.
Publicado: (2009)

Clobazam‐treated patients with Lennox‐Gastaut syndrome experienced fewer seizure‐related injuries than placebo patients during trial OV‐1012
por: Isojarvi, Jouko, et al.
Publicado: (2016)

Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
por: Sanyal, Debmalya, et al.
Publicado: (2013)

Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction
por: Redgrave, Rachael E., et al.
Publicado: (2023)

Acute myocardial infarction in von Willebrand disease: characteristics and outcomes
por: Leiva, Orly, et al.
Publicado: (2023)

Ambient Temperature and Myocardial Infarction: Who Is at Risk?
por: Lowry, Matthew T.H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v5f0fpltdolgm5di4an64m59rb